A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling.
A Crohn's Disease-associated IL2RA Enhancer Variant Determines the Balance of T Cell Immunity by Regulating Responsiveness to IL-2 Signalling.
复制标题
克罗恩疾病相关的IL2RA增强子变体通过调节对IL-2信号的反应性来决定T细胞免疫的平衡。
DOI:
10.1093/ecco-jcc/jjab103
复制
发表时间:
2021-12-18
期刊:
影响因子:
--
通讯作者:
Lord GM
中科院分区:
文献类型:
--
作者:
Goldberg R;Clough JN;Roberts LB;Sanchez J;Kordasti S;Petrov N;Hertweck A;Lorenc A;Jackson I;Tasker S;Appios A;Omer O;Parkes M;Prescott N;Jenner RG;Irving PM;Lord GM
Differential responsiveness to interleukin [IL]-2 between effector CD4+ T cells [Teff] and regulatory T cells [Treg] is a fundamental mechanism of immunoregulation. The single nucleotide polymorphism [SNP] rs61839660, located within IL2RA [CD25], has been associated with the development of Crohn’s disease [CD]. We sought to identify the T cell immune phenotype of IBD patients who carry this SNP. Teff and Treg were isolated from individuals homozygous [TT], heterozygous [CT], or wild-type [CC] for the minor allele at rs61839660, and used for phenotyping [flow cytometry, Cytometry Time Of Flight] functional assays or T cell receptor [TCR] sequencing. Phosphorylation of signal transducer and activator of transcription 5 [STAT5] was assessed in response to IL-2, IL-7, and in the presence of basiliximab, a monoclonal antibody directed against CD25. Teff pro-inflammatory cytokine expression levels were assessed by reverse transcription quantitative polymerase chain reaction after IL-2 and/or TCR stimulation. Presence of the minor T allele enhances CD25 expression, leading to increased STAT5 phosphorylation and pro-inflammatory cytokine transcript expression by Teff in response to IL-2 stimulation in vitro. Teff from TT individuals demonstrate a more activated gut homing phenotype. TCR sequencing analysis suggests that TT patients may have a reduced clonal capacity to mount an optimal regulatory T cell response. rs61839660 regulates the responsiveness of T cells to IL-2 signalling by modulating CD25 expression. As low-dose IL-2 is being trialled as a selective Treg modulator in CD, these findings highlight the potential for adverse effects in patients with this genotype.
登录
查看更多内容
DOI:
10.1084/jem.20060772
发表时间:
2006-07-10
期刊:
The Journal of experimental medicine
影响因子:
--
作者:
通讯作者:
--
影响因子:
4.6
作者:
Kircher, B;Lätzer, K;Nachbaur, D
通讯作者:
Nachbaur, D
影响因子:
64.8
作者:
Simeonov DR;Gowen BG;Boontanrart M;Roth TL;Gagnon JD;Mumbach MR;Satpathy AT;Lee Y;Bray NL;Chan AY;Lituiev DS;Nguyen ML;Gate RE;Subramaniam M;Li Z;Woo JM;Mitros T;Ray GJ;Curie GL;Naddaf N;Chu JS;Ma H;Boyer E;Van Gool F;Huang H;Liu R;Tobin VR;Schumann K;Daly MJ;Farh KK;Ansel KM;Ye CJ;Greenleaf WJ;Anderson MS;Bluestone JA;Chang HY;Corn JE;Marson A
通讯作者:
Marson A
影响因子:
48
作者:
Diggins KE;Greenplate AR;Leelatian N;Wogsland CE;Irish JM
通讯作者:
Irish JM
影响因子:
56.9
作者:
Hori, S;Nomura, T;Sakaguchi, S
通讯作者:
Sakaguchi, S